摘要
原发性肺癌是肿瘤相关死亡率较高的恶性肿瘤之一,非小细胞肺癌约占原发性肺癌的85%。近年来,由于医疗技术水平的提升和健康体检的普及,早期非小细胞肺癌检出率逐渐提高。早期NSCLC的治疗方式主要是手术切除和辅助治疗,但ⅠB期患者在肿瘤完全切除术后的辅助治疗及随访管理存在诸多争议。这篇综述聚焦于ⅠB期NSCLC患者完全切除后辅助化疗、靶向及免疫治疗选择的关键问题,同时探讨了筛选早期NSCLC高危患者的生物标志物及预后因子。
Lung cancer is considered as the leading cause of cancer-related mortality worldwide.Non-small cell lung cancer(NSCLC)accounts for about 85%of primary lung cancer.Owing to the improved utilization of medical technological level and the popularization of health examinations,the detection rate of early-stage NSCLC is gradually increasing.The main treatment modalities for early-stage NSCLC are surgical resection and adjuvant chemotherapy.Platinum-based chemotherapy is recommended as the standard postoperative adjuvant treatment for patients with completely resected stageⅡ-ⅢA NSCLC.However,adjuvant therapy remains a controversial option in stageⅠB NSCLC.This review focuses on postoperative adjuvant therapy such as adjuvant chemotherapy,targeted therapy,and immunotherapy for completely resected stageⅠB NSCLC.Moreover,the biomarkers and prognostic factors of high-risk patients are discussed.
作者
马师师
代雨然
陈晓品
MA Shishi;DAI Yuran;CHEN Xiaopin(Department of Oncology,The First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China;Department of Breast and Thyroid Surgery,The First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)
出处
《肿瘤防治研究》
CAS
2023年第3期303-308,共6页
Cancer Research on Prevention and Treatment
关键词
非小细胞肺癌
辅助化疗
靶向治疗
免疫治疗
预后因子
Non-small cell lung cancer
Adjuvant chemotherapy
Targeted therapy
Immunotherapy
Prognostic factors Competing interests:The authors declare that they have no competing interests.
